{"title":"HER2过表达对胆管内乳头状肿瘤预后的影响。","authors":"Shunsuke Onoe, Takashi Mizuno, Nobuyuki Watanabe, Shoji Kawakatsu, Junpei Yamaguchi, Taisuke Baba, Ryusei Yamamoto, Yoshie Shimoyama, Toshio Kokuryo, Tomoki Ebata","doi":"10.1002/jhbp.70000","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Overexpression of human epidermal growth factor receptor 2 (HER2) is a recognized prognostic marker and therapeutic target in oncology. However, its clinical significance in intraductal papillary neoplasm of the bile duct (IPNB) remains unclear.</p><p><strong>Methods: </strong>This retrospective study reviewed patients who underwent resection for IPNB between 1998 and 2011. HER2 overexpression was evaluated by immunohistochemistry and semi-quantitatively categorized into four grades (score 0, 1+, 2+, 3+); the former two and the latter two grades defined HER2-negative and HER2-positive groups, respectively.</p><p><strong>Results: </strong>A total of 184 IPNB cases were analyzed, of which 12 patients (6.5%) were diagnosed with HER2-positive disease. There were no significant differences between the groups in clinicopathologic characteristics such as tumor location, histologic type, or invasion depth, with the exception of superficial extension, which was significantly more frequent in the HER2-positive group. The HER2-positive group demonstrated significantly worse overall survival than the HER2-negative group (25% vs. 49% at 5 years, p = 0.030). In multivariable analysis, HER2 positivity, age ≥ 70, percutaneous transhepatic biliary drainage, nodal metastasis, and positive margin status were identified as independent prognostic factors.</p><p><strong>Conclusion: </strong>HER2 overexpression is an independent biologic marker for unfavorable survival, though infrequent in IPNB.</p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic Impact of HER2 Overexpression in Intraductal Papillary Neoplasm of the Bile Duct.\",\"authors\":\"Shunsuke Onoe, Takashi Mizuno, Nobuyuki Watanabe, Shoji Kawakatsu, Junpei Yamaguchi, Taisuke Baba, Ryusei Yamamoto, Yoshie Shimoyama, Toshio Kokuryo, Tomoki Ebata\",\"doi\":\"10.1002/jhbp.70000\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Overexpression of human epidermal growth factor receptor 2 (HER2) is a recognized prognostic marker and therapeutic target in oncology. However, its clinical significance in intraductal papillary neoplasm of the bile duct (IPNB) remains unclear.</p><p><strong>Methods: </strong>This retrospective study reviewed patients who underwent resection for IPNB between 1998 and 2011. HER2 overexpression was evaluated by immunohistochemistry and semi-quantitatively categorized into four grades (score 0, 1+, 2+, 3+); the former two and the latter two grades defined HER2-negative and HER2-positive groups, respectively.</p><p><strong>Results: </strong>A total of 184 IPNB cases were analyzed, of which 12 patients (6.5%) were diagnosed with HER2-positive disease. There were no significant differences between the groups in clinicopathologic characteristics such as tumor location, histologic type, or invasion depth, with the exception of superficial extension, which was significantly more frequent in the HER2-positive group. The HER2-positive group demonstrated significantly worse overall survival than the HER2-negative group (25% vs. 49% at 5 years, p = 0.030). In multivariable analysis, HER2 positivity, age ≥ 70, percutaneous transhepatic biliary drainage, nodal metastasis, and positive margin status were identified as independent prognostic factors.</p><p><strong>Conclusion: </strong>HER2 overexpression is an independent biologic marker for unfavorable survival, though infrequent in IPNB.</p>\",\"PeriodicalId\":16056,\"journal\":{\"name\":\"Journal of Hepato‐Biliary‐Pancreatic Sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepato‐Biliary‐Pancreatic Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/jhbp.70000\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepato‐Biliary‐Pancreatic Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jhbp.70000","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:人表皮生长因子受体2 (HER2)的过表达是公认的肿瘤预后标志物和治疗靶点。然而,其在胆管内乳头状瘤(IPNB)中的临床意义尚不清楚。方法:本回顾性研究回顾了1998年至2011年间接受IPNB切除术的患者。免疫组化评价HER2过表达,半定量分为0、1+、2+、3+ 4个等级;前两个分级和后两个分级分别定义her2阴性组和her2阳性组。结果:共分析184例IPNB,其中12例(6.5%)诊断为her2阳性疾病。两组间在肿瘤位置、组织学类型、侵袭深度等临床病理特征上均无显著差异,但her2阳性组明显多发于浅表延伸。her2阳性组的总生存率明显低于her2阴性组(5年生存率为25% vs. 49%, p = 0.030)。在多变量分析中,HER2阳性,年龄≥70岁,经皮经肝胆道引流,淋巴结转移和阳性边缘状态被确定为独立的预后因素。结论:HER2过表达是不利生存的独立生物学标志物,尽管在IPNB中并不常见。
Prognostic Impact of HER2 Overexpression in Intraductal Papillary Neoplasm of the Bile Duct.
Background: Overexpression of human epidermal growth factor receptor 2 (HER2) is a recognized prognostic marker and therapeutic target in oncology. However, its clinical significance in intraductal papillary neoplasm of the bile duct (IPNB) remains unclear.
Methods: This retrospective study reviewed patients who underwent resection for IPNB between 1998 and 2011. HER2 overexpression was evaluated by immunohistochemistry and semi-quantitatively categorized into four grades (score 0, 1+, 2+, 3+); the former two and the latter two grades defined HER2-negative and HER2-positive groups, respectively.
Results: A total of 184 IPNB cases were analyzed, of which 12 patients (6.5%) were diagnosed with HER2-positive disease. There were no significant differences between the groups in clinicopathologic characteristics such as tumor location, histologic type, or invasion depth, with the exception of superficial extension, which was significantly more frequent in the HER2-positive group. The HER2-positive group demonstrated significantly worse overall survival than the HER2-negative group (25% vs. 49% at 5 years, p = 0.030). In multivariable analysis, HER2 positivity, age ≥ 70, percutaneous transhepatic biliary drainage, nodal metastasis, and positive margin status were identified as independent prognostic factors.
Conclusion: HER2 overexpression is an independent biologic marker for unfavorable survival, though infrequent in IPNB.
期刊介绍:
The Journal of Hepato-Biliary-Pancreatic Sciences (JHBPS) is the leading peer-reviewed journal in the field of hepato-biliary-pancreatic sciences. JHBPS publishes articles dealing with clinical research as well as translational research on all aspects of this field. Coverage includes Original Article, Review Article, Images of Interest, Rapid Communication and an announcement section. Letters to the Editor and comments on the journal’s policies or content are also included. JHBPS welcomes submissions from surgeons, physicians, endoscopists, radiologists, oncologists, and pathologists.